Literature DB >> 23334092

Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer.

David Ball1, Alan Mitchell, Dori Giroux, Ramon Rami-Porta.   

Abstract

BACKGROUND: Analysis of the International Association for the Study of Lung Cancer database revealed that for patients with completely resected, node-negative, non-small-cell lung cancer (NSCLC), increasing tumor size was associated with worsening survival. This analysis was performed to determine the effect of size on prognosis in patients in the same database but who were treated with radiotherapy or chemoradiotherapy.
METHODS: Patients were eligible if they had pathologically confirmed NSCLC, no evidence of distant metastases, intended treatment was radical radiotherapy (minimum 50 Gy) or combined chemotherapy and radiotherapy, no surgery, and tumor diameter was available.
RESULTS: Eight hundred and sixty-eight patients were available for analysis. Patient characteristics were: sex (men) 65.3%; median age 64 years (range, 32-88); Eastern Cooperative Oncology Group performance status 0: 55%, 1: 33%, 2 or more: 5%; chemotherapy 74%; no chemotherapy 18%; weight loss less than 5 %: 70%, and more than 5%: 25%. Primary tumor size was categorized according to tumor, node, metastasis 7th edition. On univariate analysis, the following factors were prognostic for survival: age (continuous) (p = 0.0035); performance status of 1 or more (p = 0.0021); weight loss less than 5% (p < 0.0001); chemotherapy (p = 0.0189); and primary tumor size (continuous) (p = 0.0002). Sex and clinical nodal stage were not significant. On multivariate analysis, age and weight loss remained significant factors for survival, as was tumor size less than 3 cm.
CONCLUSIONS: In patients treated with radiotherapy with or without chemotherapy, tumor size less than 3 cm was associated with longer survival than larger tumors. Evidence of the effect of size on prognosis above this was weak. Five-year survival of more than 10% was observed in all four size categories.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334092     DOI: 10.1097/JTO.0b013e31827dc74d

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  26 in total

1.  A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making.

Authors:  Cary Oberije; Georgi Nalbantov; Andre Dekker; Liesbeth Boersma; Jacques Borger; Bart Reymen; Angela van Baardwijk; Rinus Wanders; Dirk De Ruysscher; Ewout Steyerberg; Anne-Marie Dingemans; Philippe Lambin
Journal:  Radiother Oncol       Date:  2014-05-17       Impact factor: 6.280

Review 2.  Adjuvant or neoadjuvant chemotherapy for NSCLC.

Authors:  Philip McElnay; Eric Lim
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

3.  TNM in non-small cell lung cancer: a staging system for all oncologists or just for surgeons?

Authors:  David Ball
Journal:  Ann Transl Med       Date:  2019-07

4.  Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation.

Authors:  Ramón Palmero; Arturo Navarro-Martin; Ernest Nadal
Journal:  Ann Transl Med       Date:  2019-07

5.  Synthesis, characterization and anticancer activity of Fe(II) and Fe(III) complexes containing N-(8-quinolyl)salicylaldimine Schiff base ligands.

Authors:  Sutthida Wongsuwan; Jaruwan Chatwichien; Bussaba Pinchaipat; Sarawut Kumphune; David J Harding; Phimphaka Harding; Jaursup Boonmak; Sujittra Youngme; Ratanon Chotima
Journal:  J Biol Inorg Chem       Date:  2021-02-19       Impact factor: 3.358

6.  Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.

Authors:  Jianjun Zhang; Kathryn A Gold; Heather Y Lin; Stephen G Swisher; Yan Xing; J Jack Lee; Edward S Kim; William N William
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

7.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Authors:  Vinita Popat; Rong Lu; Murtaza Ahmed; Jason Y Park; Yang Xie; David E Gerber
Journal:  Oncologist       Date:  2020-03-31

9.  Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients.

Authors:  Xiaoting Tao; Chongze Yuan; Difan Zheng; Ting Ye; Yunjian Pan; Yawei Zhang; Jiaqing Xiang; Hong Hu; Haiquan Chen; Yihua Sun
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

10.  Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy.

Authors:  Lin Yang; Yikun Yang; Peiqing Ma; Bo Zheng; Wenchao Liu; Zhirong Zhang; Ningning Ding; Li Liu; Yousheng Mao; Ning Lv
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.